P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood–brain barrier in vivo

P-Glycoprotein, a gatekeeper in the blood–brain barrier

Alfred H. Schinkel · Advanced Drug Delivery Reviews · 1999 · 954 citations

Medicine, Neuroscience, Pharmacology +8

Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors

Yasuo Uchida, Sumio Ohtsuki, Yuki Katsukura et al. · Journal of Neurochemistry · 2011 · 909 citations

Life Sciences, Biochemistry, Pharmacology +15

Quantitative Atlas of Membrane Transporter Proteins: Development and Application of a Highly Sensitive Simultaneous LC/MS/MS Method Combined with Novel In-silico Peptide Selection Criteria

Junichi Kamiie, Sumio Ohtsuki, Ryo Iwase et al. · Pharmaceutical Research · 2008 · 479 citations

Life Sciences, Biochemistry, Molecular Biology +12

In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System

Bo Feng, Jessica B. Mills, Ralph E. Davidson et al. · Drug Metabolism and Disposition · 2007 · 442 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL

Angela C. Doran, R. Scott Obach, Bill J. Smith et al. · Drug Metabolism and Disposition · 2004 · 440 citations

Medicine, Pharmacokinetics, Pharmacology +16